Two new blood tests for biomarkers that correlate with brain amyloid beta pathology have been cleared by the FDA to aid in the diagnosis of Alzheimer's disease (AD): Elecsys Phospho-Tau (217P) Plasma assay (Roche) and PrecivityAD2 (C2N Diagnostics). Other FDA-cleared blood tests for AD biomarkers are listed in Table 1.1,2 The amyloid beta-directed antibodies lecanemab (Leqembi, and others) and donanemab (Kisunla) are available for treatment of AD in patients with mild cognitive impairment or mild dementia who have confirmed brain amyloid pathology.
RELEASE
The FDA is requiring that a warning about a risk of nonarteritic anterior ischemic optic neuropathy (NAION) be added to the package inserts of the GLP-1 receptor agonists dulaglutide (Trulicity), exenatide, liraglutide (Saxenda, Victoza), semaglutide (Ozempic, Rybelsus, Wegovy), and orforglipron (Foundayo) and the dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonist tirzepatide (Mounjaro, Zepbound).1
NAION — NAION is caused by reduced blood flow to the optic nerve. It is a common cause of acute optic nerve injury in adults >50 years old (incidence is 2.3-10.2 cases per 100,000 person-years).2 Patients typically present with sudden, painless vision loss in one eye, accompanied by reduced visual acuity and visual field defects. Vision loss can be permanent.3 Patients with a history of NAION are at increased risk of recurrence.
…






